Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475559 | 0.91 | PDE4B (0.59) | GPR119PDE4BLMNAFAAHTP53 | |
| SCHEMBL25321732 | 0.91 | PDE4B (0.59) | GPR119PDE4BLMNAFAAHTP53 | |
| SCHEMBL25320477 | 0.91 | PDE4B (0.59) | GPR119PDE4BLMNAFAAHTP53 | |
| SCHEMBL25320873 | 0.91 | PDE4B (0.59) | GPR119PDE4BLMNAFAAHTP53 | |
| SCHEMBL1673519 | 0.85 | GPR119 (0.63) | GPR119PDE4BLMNAFAAHNAMPT | |
| SCHEMBL10163045 | 0.84 | PDE4B (0.55) | PDE4BRECQLSMN1; SMN2LMNAFAAH | |
| SCHEMBL1673472 | 0.82 | GPR119 (0.51) | GPR119PDE4BLMNATP53NAMPT | |
| SCHEMBL10163606 | 0.82 | PDE4B (0.50) | PDE4BFAAH | |
| SCHEMBL25321447 | 0.82 | GPR119 (0.55) | GPR119PDE4BSMN1; SMN2LMNATGFBR1 | |
| SCHEMBL12321142 | 0.82 | PDE4B (0.60) | GPR119PDE4BSMN1; SMN2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | GPR119 1235/4885PDE4B 450/4885USP30 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.